SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis
7 references·7 citing·45 second hop
Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis (2017)Toward a Broader Concept of Value: Identi…Measuring the Value of Prescription Drugs (2015)Measuring the Value of Prescr…Encyclopedia of Health Economics (2014)Encyclopedia of Health Econom…Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context (2013)Value‐Based Differential Pric…How Cancer Patients Value Hope And The Implications For Cost-Effectiveness Assessments Of High-Cost Cancer Therapies (2012)How Cancer Patients Value Hop…Willingness‐to‐pay for predictive tests with no immediate treatment implications: a survey of US residents (2010)Willingness‐to‐pay for predic…Economic foundations of cost-effectiveness analysis (1997)Economic foundations of cost-…Foundations of Cost-Effectiveness Analysis for Health and Medical Practices (1977)Foundations of Cost-Effective…A Roadmap for Increasing the Usefulness and Impact of Patient-Preference Studies in Decision Making in Health: A Good Practices Report of an ISPOR Task Force (2023)A Roadmap for Increasing the …The History and Future of the “ISPOR Value Flower”: Addressing Limitations of Conventional Cost-Effectiveness Analysis (2022)The History and Future of the…Pricing as a driver of profitable growth: An agenda for CEOs and senior executives (2021)Pricing as a driver of profit…Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications (2021)Potential approaches for the …Defining the concept of fair pricing for medicines (2020)Defining the concept of fair …Value-Based Pricing for Emerging Gene Therapies: The Economic Case for a Higher Cost-Effectiveness Threshold (2019)Value-Based Pricing for Emerg…Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Economics (2017)Value-Based Pricing and Reimb…Parallel imports, demand dispersion, and international price discrimination (1994)Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents (2003)Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer (2015)Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness (2015)Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use (2016)The Utility Analysis of Choices Involving Risk (1948)The contingent valuation method in health care (1999)Valuing health care using willingness to pay: a comparison of the payment card and dichotomous choice methods (2003)Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare (2018)Health technology assessment with risk aversion in health (2020)Health Technology Assessment With Diminishing Returns to Health: The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Approach (2021)Risk, Ambiguity, and the Savage Axioms (1961)Statistical Efficiency of Double‐Bounded Dichotomous Choice Contingent Valuation (1991)Recommendations of the Panel on Cost-Effectiveness in Health and Medicine (1996)Assessing the Added Value of Health Technologies: Reconciling Different Perspectives (2012)Concepts of ‘Personalization’ in Personalized Medicine: Implications for Economic Evaluation (2014)American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for Oncology (2012)The Strategy That Will Fix Health Care (2013)American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options (2015)Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks (2017)Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015 (2017)A Health Economics Approach to US Value Assessment Frameworks—Introduction: An ISPOR Special Task Force Report [1] (2018)The Value of a Statistical Life: A Critical Review of Market Estimates Throughout the World (2003)Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold (2014)Cost-Effectiveness in Health and Medicine (2016)Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy (2019)Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations? (2021)Risk Aversion in the Small and in the Large (1964)Cost-Effectiveness in Health and Medicine (1996)Decision Making in Health and Medicine: Integrating Evidence and Values (2001)The Value of a Statistical Life: A Critical Review of Market Estimates Throughout the World (2002)Methods for the Economic Evaluation of Health Care Programmes (2005)Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold (2008)Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3] (2018)Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations (2022)Measurement of health state utilities for economic appraisal (1986)Conjoint Analysis Applications in Health—a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force (2011)Constructing Experimental Designs for Discrete-Choice Experiments: Report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force (2013)Pretesting Discrete-Choice Experiments: A Guide for Researchers (2024)The rise of best-worst scaling for prioritization: A transdisciplinary literature review (2024)Utility approach to measuring health-related quality of life (1987)Recommendations for Reporting Cost-effectiveness Analyses (1996)Comparing and Explaining Differences in the Magnitude, Content, and Sensitivity of Utilities Predicted by the EQ-5D, SF-6D, HUI 3, 15D, QWB, and AQoL-8D Multiattribute Utility Instruments (2014)A Review of the Development and Application of Generic Multi-Attribute Utility Instruments for Paediatric Populations (2015)Patient and general public preferences for health states: A call to reconsider current guidelines (2016)
this work references cited by second hop

References

  • 1977Foundations of Cost-Effectiveness Analysis for Health and Medical Practices2,118 cited
  • 1997Economic foundations of cost-effectiveness analysis767 cited
  • 2014Encyclopedia of Health Economics217 cited
  • 2015Measuring the Value of Prescription Drugs144 cited
  • 2013Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context142 cited
  • 2010Willingness‐to‐pay for predictive tests with no immediate treatment implications: a survey of US residents141 cited
  • 2012How Cancer Patients Value Hope And The Implications For Cost-Effectiveness Assessments Of High-Cost Cancer Therapies128 cited

Cited by

  • 2019Value-Based Pricing for Emerging Gene Therapies: The Economic Case for a Higher Cost-Effectiveness Threshold93 cited
  • 2022The History and Future of the “ISPOR Value Flower”: Addressing Limitations of Conventional Cost-Effectiveness Analysis92 cited
  • 2023A Roadmap for Increasing the Usefulness and Impact of Patient-Preference Studies in Decision Making in Health: A Good Practices Report of an ISPOR Task Force90 cited
  • 2017Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Economics84 cited
  • 2021Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications75 cited
  • 2020Defining the concept of fair pricing for medicines

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

65 cited
  • 2021Pricing as a driver of profitable growth: An agenda for CEOs and senior executives14 cited